New Slow-Release schizophrenia shot studied in 106 patients

NCT ID NCT06319170

First seen Jan 11, 2026 · Last updated Jun 14, 2026 · Updated 19 times

Summary

This study tested three different slow-release versions of the drug olanzapine given as a shot under the skin. Researchers wanted to see how the drug behaves in the body and whether it is safe. 106 adults with schizophrenia or schizoaffective disorder took part. The goal is to find a longer-acting option that helps control symptoms with fewer injections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA / SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Teva Investigational Site 15726

    Marlton, New Jersey, 08053, United States

  • Teva Investigational Site 15727

    Hollywood, Florida, 33024, United States

  • Teva Investigational Site 15728

    Decatur, Georgia, 30030, United States

  • Teva Investigational Site 15729

    Atlanta, Georgia, 30331, United States

  • Teva Investigational Site 15730

    Los Alamitos, California, 90720, United States

Conditions

Explore the condition pages connected to this study.